High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline

Stage IIB Hodgkin lymphoma (HL) patients, with a mediastinum-to-thorax (M/T) ratio of ≥0.33 or extranodal localization have a poor prognosis and are treated either as limited or advanced stage. We compared these two approaches in patients included in two randomized phase III trials enrolling previou...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Cédric, André, Marc, Dupuis, Jehan, Morschhauser, Franck, Joly, Bertrand, Lazarovici, Julien, Ghesquières, Hervé, Stamatoullas, Aspasia, Nicolas-Virelizier, Emmanuelle, Feugier, Pierre, Gac, Anne-Claire, Moatti, Hannah, Fornecker, Luc-Matthieu, Deau, Bénédicte, Joubert, Clémentine, Fortpied, Catherine, Raemaekers, John, Federico, Massimo, Kanoun, Salim, Meignan, Michel, Traverse-Glehen, Alexandra, Cottereau, Anne-Ségolène, Casasnovas, René-Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Hodgkin Lymphoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713544/
https://www.ncbi.nlm.nih.gov/pubmed/35638548
http://dx.doi.org/10.3324/haematol.2021.280004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713544/
https://www.ncbi.nlm.nih.gov/pubmed/35638548
http://dx.doi.org/10.3324/haematol.2021.280004

Ejemplares similares